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Highlights 
 
- Objective/subjective depression severity affects subjective cognitive impairment. 
- Subjective remission seems more correlated with subjective cognitive function. 
- Objective remission alone does not represent favorable cognitive function. 
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Abstract 
Objective: The impact of subjective versus objective illness severity on subjective cognitive impairment in 
patients with depression has not been addressed. 
Methods: This study is a post-hoc analysis of our cross-sectional study in Japanese outpatients with 
depressive disorder (ICD-10) (Ozawa et al., 2017). The participants received assessments with the Japanese 
version of the Perceived Deficits Questionnaire (J-PDQ), Quick Inventory of Depressive Symptomatology 
(QIDS), and Montgomery-Asberg Depression Rating Scale (MADRS). First, multiple regression analysis 
was conducted to examine the effects of demographic and clinical characteristics, including illness severity 
and medications (e.g., antidepressants and benzodiazepines), on the PDQ total score. Next, we categorized 
the participants into 4 groups based on the presence/absence of subjective and objective symptom remission 
(i.e., QIDS total score of ≤5 and MADRS total score of ≤9, respectively), and compared the differences in 
PDQ total scores between the QIDS- and MADRS-remitted group and the QIDS-non-remitted but 
MADRS-remitted group. 
Results: 102 participants were included (45 men; mean±SD age, 50.5±14.7 years). Higher QIDS and 
MADRS total scores were significantly associated with a greater PDQ total score (both p’s<0.001), while 
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other factors did not exhibit any associations. The QIDS-non-remitted but MADRS-remitted group showed 
a significantly higher PDQ total score than that of the QIDS- and MADRS-remitted group (median 10.0 
[8.0-12.0] vs. 3.0 [range: 2.0-4.0], p<0.001). 
Conclusions: These findings suggest that objective remission in the absence of subjective remission may 
not be adequate to improve subjective cognitive functioning. 
 
Keywords: depression, illness severity, PDQ, subjective cognitive impairment 
 
1. Introduction 
 
Cognitive impairment is a common symptom of major depressive disorder (MDD) with prevalence rates 
ranging from 20% to 60% (Afridi et al., 2011; Gualtieri and Morgan, 2008). While research often prioritizes 
mood symptoms because of the illness’s affective nature, it is also critically important to focus on cognitive 
impairment in light of its close associations with poor treatment response and low psychosocial functioning 
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(Evans et al., 2014; Story et al., 2008). Patients with MDD have reported impairment in several domains of 
cognition, including working memory, social cognition, reasoning/problem solving, motor speed, and 
attention (Bakkour et al., 2014). A meta-analysis indicated moderate impairments in several cognitive 
domains in patients with MDD as compared to healthy controls (Cohen’s d: -0.34 to -0.54 in executive 
function, -0.41 to -0.50 in memory, and -0.65 in attention, respectively) (Rock et al., 2014). 
Previous studies have shown that cognitive impairment remains unresolved in some patients who have 
already remitted from depressive episodes, although this finding has not been consistent in the literature 
(Baba et al., 2010; Conradi et al., 2011; Nagane et al., 2014; Paelecke-Habermann et al., 2005). One recent 
randomized longitudinal study, which included 712 patients with MDD, demonstrated that cognitive 
impairment remained unresolved in five domains (attention, response inhibition, verbal memory, decision 
speed, and information processing) following antidepressant treatment, even among remitted patients 
(Shilyansky et al., 2016). Thus, there is a clear need to attend to cognitive function in patients with MDD 
regardless of their remission status. 
 
Cognitive function can be evaluated with subjective and/or objective assessment measures in depression 
(Antikainen et al., 2001; Svendsen et al., 2012). Previous studies that investigated the concordance between 
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subjective and objective cognitive function in older adults has produced highly varied findings (Burmester 
et al., 2016). As for mood disorders, one study reported the positive association between subjectively and 
objectively assessed cognitive functions in patients with bipolar disorder (Arts et al., 2010). Recent 
evidence suggests that subjectively assessed cognitive measures are more closely correlated with general 
functioning and depressive symptoms than objective measures in patients with MDD (Potvin et al., 2016; 
Zlatar et al., 2018). The symptomatology of depression has similarly been assessed with subjective and/or 
objective assessment scales (Trivedi, 2009). However, the degree of concordance between subjective and 
objective measures in assessments of illness severity varies (Carter et al., 2010; Tada et al., 2014; Uher et al., 
2012). Thus, it is plausible that subjective and objective illness severity has different effects on subjective 
cognitive impairment in patients with MDD. Furthermore, while objectively assessed cognitive impairment 
appears to be affected by the severity of depression, duration of illness, and medications used (Borkowska 
and Rybakowski, 2001; Federico et al., 2017; Gorenstein et al., 2006; Hasselbalch et al., 2011; Tourjman et 
al., 2018), it remains unclear which demographic and clinical factors affect subjective cognitive 
impairment. 
 
In this study, we therefore explored factors associated with subjective cognitive impairment and 
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investigated differences in the impact of subjective versus objective illness severity on subjective cognitive 
impairment in patients with MDD. 
 
2. Methods 
 
2.1.Study design and participants 
We conducted a post-hoc analysis of the data from our previous cross-sectional study investigating factors 
associated with resilience in patients with depression. The research conditions have been described in detail 
elsewhere (Ozawa et al., 2017). Briefly, the study was conducted between November 2014 and September 
2016 at 10 psychiatric hospitals and clinics in Japan. One hundred and twelve outpatients aged ≥18 years 
with a diagnosis of depressive disorder based on the International Classification of Disease and related 
Health Problems, 10th Revision (ICD-10) (World Health Organization, 1993) participated in the study. 
Patients with a history of epilepsy or organic mental disorders, mental retardation, active substance abuse, 
or those judged to have active suicidal ideation or severe physical impairments by their treating 
psychiatrists were excluded. The participants were assessed with the Japanese version of the Quick 
Inventory of Depressive Symptomatology (QIDS) (Rush et al., 2003) for subjective symptomatology, the 
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Montgomery-Asberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979) for objective 
symptomatology, and the Japanese version of the Perceived Deficits Questionnaire (J-PDQ) (Sullivan et al., 
1990) for subjective cognitive impairment. The J-PDQ consists of 20 items, and each item is scored on a 
5-point scale with a total score ranging from 0-80; higher scores indicate greater levels of subjective 
cognitive impairment. The PDQ was translated into Japanese by two authors (CO and YM) and then 
back-translated into English by another two (EBR and HU), who were not aware of the original English 
version. The scale’s developer (M. J. Sullivan) confirmed the back-translated version with regard to 
accuracy and context. The participants were asked to fill in the J-PDQ at baseline and 3-5 days later. The 
internal consistency of the J-PDQ was examined with Cronbach’s alpha coefficient and test-retest reliability 
of the J-PDQ scores at baseline, and follow-up was addressed using the intra-class correlation coefficient 
(ICC). Cronbach’s alpha coefficient and the ICC were found to be high at 0.94 and 0.93, respectively. Other 
participant information collected included age, sex, duration of illness, and prescribed psychotropic 
medications. We calculated daily doses of antidepressants in imipramine equivalents (IMIE) (Inagaki and 
Inada, 2018), benzodiazepines in diazepam equivalents (DZPE) (Inada and Inagaki, 2015), and 
antipsychotics in chlorpromazine equivalents (CPZE) (Inada and Inagaki, 2015). 
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The original study was approved by the institutional review board at each participating site, and all 
participants provided written informed consent after receiving detailed information about the study. 
 
2.2 Statistical analysis 
Spearman’s correlation analysis was used to examine the relationship between the J-PDQ total scores and 
the QIDS or MADRS total scores. Then, multiple linear regression analysis (forced entry model) was 
performed to identify factors that were associated with the J-PDQ total score. The following factors were 
included as independent variables: age, sex, duration of illness, IMIE, DZPE, CPZE, and total scores on the 
QIDS or MADRS. The Shapiro-Wilk test was used to test continuous variables for normality. Next, we 
categorized the participants into four groups based on the presence/absence of subjective symptom 
remission (i.e., a QIDS total score of ≤5) (Trivedi et al., 2006) and objective symptom remission (i.e., a 
MADRS total score of ≤9) (Zimmerman et al., 2004). Due to non-normal distribution of the data, 
differences in the J-PDQ total scores were compared between three groups (the QIDS- and 
MADRS-remitted group, the QIDS-non-remitted but MADRS-remitted group, and the QIDS-remitted but 
MADRS-non-remitted group) using a Kruskal-Wallis test. Moreover, the QIDS- and MADRS-remitted 
group was compared with the QIDS-non-remitted but MADRS-remitted group and the QIDS-remitted but 
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MADRS-non-remitted group using Mann-Whitney’s U test, with Bonferroni correction applied. A p-value 
of <0.05 was considered statistically significant (two-tailed). These statistical analyses were performed 
using SPSS version 24.0 (IBM Corp., Armonk, NY) and PRISM Version 7 (GraphPad Software, Inc, San 
Diego, CA). 
 
3. Results 
 
3.1 Participants characteristics 
One hundred participants were included in the original study, and two additional participants, whose data 
became available after the study’s final analyses, were also included in the present study. One participant 
did not complete the QIDS questionnaire. Thus, the data from 102 and 101 participants were used for the 
analyses with respect to the MADRS and QIDS scores, respectively. Demographic and clinical 
characteristics of the participants are summarized in Table 1. 
 
-------------------------------------- 
Insert Table 1 Here 
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-------------------------------------- 
 
3.2 Factors associated with subjective cognitive impairment 
The MADRS and QIDS total scores were significantly correlated with the J-PDQ total scores (r=0.635, 
p<0.001 and r=0.789, p<0.001, respectively); the greater correlation was found in the QIDS total scores 
compared to the MADRS total scores (Figures 1 and 2). Next, in a multiple linear regression analysis 
including the MADRS total scores for symptom severity, there was a significant positive association with 
the J-PDQ total scores (β=0.621, p<0.001) (Table 2). Similarly, greater QIDS total scores were associated 
with greater J-PDQ scores (β=0.838, p<0.001) while female sex was associated with lesser J-PDQ scores 
(β=-0.138, p=0.029) (Table 3). Other factors, including medications, did not exhibit any significant 
associations with the J-PDQ total scores. 
 
-------------------------------------- 
Insert Figures 1 and 2, and Tables 2 and 3 Here 
-------------------------------------- 
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3.3. Subjective cognitive impairment by subjectively or objectively assessed remission status 
Of the 101 participants, 33 (32.7%), 25 (24.8%), and 4 (4.0%) participants were categorized into the QIDS- 
and MADRS-remitted, the QIDS-non-remitted but MADRS-remitted, and the QIDS-remitted but 
MADRS-non-remitted groups, respectively. A Kruskal-Wallis test found a statistically significant difference 
in the J-PDQ total score among the three groups (p<0.001). The QIDS-non-remitted but MADRS-remitted 
group showed a significantly higher J-PDQ total score than the QIDS- and MADRS-remitted group, even 
after Bonferroni correction (p<0.017 [0.05/3]) (Table 4). However, no significant difference was found in 
the J-PDQ total score between the QIDS-remitted but MADRS-non-remitted group and the QIDS- and 
MADRS-remitted group (Table 5). 
 
-------------------------------------- 
Insert Tables 4 and 5 Here 
-------------------------------------- 
 
 
4. Discussion 
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This study examined factors associated with subjective cognitive impairment in patients with MDD. To the 
best of our knowledge, this is the first study to investigate the impact of subjective versus objective 
differential remission status on subjective cognitive impairment in patients with MDD. We found that 
greater illness severity assessed subjectively and objectively was significantly associated with subjective 
cognitive impairment. Furthermore, subjective cognitive impairment remained when a patient’s remission 
status was confirmed by their physician but not by the patient’s subjective assessment. 
 
Several studies have investigated the impact of illness severity on cognitive function in patients with MDD 
(Austin et al., 2001; Hasselbalch et al., 2011; McDermott and Ebmeier, 2009). For example, Lawrence and 
colleagues conducted a cross-sectional study that investigated the relationship between subjective cognitive 
impairment assessed with the PDQ and illness severity in depressed employees (Lawrence et al., 2013). 
They found that greater severity of depression was significantly associated with more severe subjective 
cognitive impairment even after controlling for covariates such as age, sex, and antidepressant use. This 
finding held across all of the PDQ’s four subscales (attention/concentration, retrospective memory, 
prospective memory, and planning/organization). Consistent with these findings, we found significant 
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associations between greater illness severity and overall subjective cognitive impairment, as well as 
impairments in the J-PDQ’s four domains in Japanese patients with MDD (Supplementary Tables 1-8). 
Since the impact of illness severity on cognitive impairment may differ across individual cognitive domains 
in patients with MDD (McDermott and Ebmeier, 2009), regular and comprehensive assessment of cognitive 
function would help identify and address clinical needs on an individual basis. 
 
Of particular note is that participants who remitted objectively but not subjectively indicated worse 
subjective cognitive performance than those who remitted subjectively as well as objectively. Although 
subjective and objective measures of depression severity may be interchangeable (Bernstein et al., 2010; 
Rush et al., 2006), they may not necessarily be equivalent in their quality and clinical relevance (Carter et 
al., 2010; Tada et al., 2014; Uher et al., 2008; Uher et al., 2012). For example, Zimmerman and colleagues 
compared symptom profiles of depression in patients in subjective remission and patients who, according to 
the Hamilton Rating Scale for Depression (HAMD), were considered to be in objective remission 
(Zimmerman et al., 2012). Approximately half of the objectively remitted patients (63/140) were not in 
subjective remission. Patients’ assessments of their symptoms may be intrinsically affected by negatively 
biased cognitive processes, such as hopelessness and low self-esteem, as well as psychomotor retardation 
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(Beevers and Miller, 2004; Crane et al., 2007). Thus, physicians need to be aware of both subjective and 
objective perspectives in determining illness severity, which may also have relevance for prognosis (Tada et 
al., 2014). 
 
In the present study, duration of illness and medications used were not associated with subjective cognitive 
impairment. Previous studies have also generally failed to find correlations between duration of illness and 
cognitive function (Biringer et al., 2007; Lampe et al., 2004; Verdoux and Liraud, 2000). Our results are in 
agreement with these findings, although previous studies have used objective assessment measures. The 
effects of antidepressants on cognitive function still remain inconclusive in patients with MDD 
(Hasselbalch et al., 2011). Notably, a recent meta-analysis reported that antidepressants have positive 
effects on cognitive function in patients with depression (Prado et al., 2018), with the exception of tricyclic 
antidepressants (TCAs). In our study, only 11 participants used TCAs, which might have resulted in the 
non-significant result. The association between cognitive impairment and benzodiazepines has been well 
documented (Barker et al., 2004; Pomara et al., 2015; van der Sluiszen et al., 2017). While we did not find 
any association between use of benzodiazepines and cognitive impairment, it should be noted that clinical 
evidence discourages routine use of benzodiazepines in light of various, sometimes serious, side effects, 
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including falls and dependence (Soyka, 2017; Wagner et al., 2004). Sex was significantly associated with 
subjective cognitive impairment only in the linear regression analysis wherein QIDS total score was entered 
as an independent variable but not in the analysis with MADRS total score. However, no significant 
association between sex and subjective cognitive impairment was found in the univariate linear regression 
analysis in which sex was entered as an independent variable (data are not shown). This may imply 
potential difference in the effect of sex on the QIDS and MADRS total scores. There was a difference in the 
coefficient of sex between the linear regression analyses wherein the MADRS and QIDS total scores were 
entered as an independent variable (i.e., -0.618 and -4.050, respectively) (Tables 2 and 3). Furthermore, 
there was a difference in the coefficient of sex between the linear regression analyses wherein the MADRS 
and QIDS total scores were entered as a dependent variable and other variables (i.e., age, sex, duration of 
illness, IMIE, CPZE, and DZPE) as independent variables (i.e., -0.82 and 1.29, respectively) (data are not 
shown). Such differences in the association between sex and the QIDS or MADRS total score may have 
resulted in the different impact of sex on J-PDQ total score that we found in this study. 
The results of our study must be interpreted in light of some limitations. First, our study was a post-hoc 
analysis of a cross-sectional study, and the topic addressed herein was not our primary focus in the original 
study. Furthermore, objective cognitive impairment was not evaluated in this study because the original 
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study focused on subjective cognitive impairment but not objective cognitive impairment in patients with 
MDD. Future work will be needed to compare the interplay between symptoms and cognition, both of 
which may be assessed subjectively as well as objectively. Second, there is a possibility that confounding 
factors we did not evaluate, including other modes of treatment—e.g., psychotherapy, number of depressive 
episodes, and number of previous hospitalizations (Hasselbalch et al., 2011)—may have affected the results. 
Third, the sample size was relatively small. In addition, there were only four participants in the 
QIDS-remitted but MADRS-non-remitted group, which may have caused a type II error. Thus, further 
investigations using larger samples are needed. Moreover, we were unable to examine which factors in the 
QIDS and MADRS affected the J-PDQ due to the small sample size, which clearly warrants further 
investigations. Fourth, the generalizability of our findings may be limited given the characteristics of 
participants, who were Japanese outpatients capable of consenting to participation in the research. Finally, 
subjective versus objective differentials in MDD may well be affected by personality, which was not 
addressed. 
 
In conclusion, greater illness severity, both subjectively and objectively, seems to negatively affect 
subjective cognitive impairment in patients with MDD. Furthermore, objective remission in the absence of 
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subjective remission may not represent favorable outcomes in terms of subjective cognitive function. 
Although future prospective studies are necessary to confirm these preliminary findings, the results of this 
study underscore the importance of focusing on both subjective and objective perspectives to enhance the 
efficacy of any treatment for patients with MDD. 
Acknowledgments 
The authors would like to thank Dr. Sullivan for his dedicated support. 
 
Role of the funding source 
None 
 
Contributors 
Drs. Sawada, Yoshida, and Uchida contributed to and have approved the design and the protocol of the 
study and the literature search. Drs. Sawada, Yoshida, and Uchida undertook the statistical analysis. Drs. 
Sawada, Yoshida, and Uchida wrote the first draft of the manuscript. All authors contributed to and have 
approved the final manuscript. 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Declaration of interest 
Dr. Yoshida has received manuscript fees from Sumitomo Dainippon Pharma, fellowship grants from the 
Japan Research Foundation for Clinical Pharmacology, and consultant fees from Bracket within the past 
three years. Dr. Ozawa has received manuscript fees from Sumitomo Dainippon Pharma in the past three 
years. Dr. Mizuno has received manuscript fees or speaker’s honoraria from Sumitomo Dainippon Pharma 
and Yoshitomi Yakuhin, fellowship grants from Japan Society for the Promotion of Science, Astellas 
Foundation for Research on Metabolic Disorders, Japanese Society of Clinical Neuropsychopharmacology, 
and Mochida Memorial Foundation for Medical and Pharmaceutical Research, and consultant fees from 
Bracket within the past three years. Dr. Suzuki has received manuscript or speaker’s fees from Astellas, 
Dainippon Sumitomo Pharma, Eli Lilly, Elsevier Japan, Janssen Pharmaceuticals, Meiji Seika Pharma, 
Novartis, Otsuka Pharmaceutical, Wiley Japan, and Yoshitomi Yakuhin, and research grants from Eisai, 
Mochida Pharmaceutical, and Meiji Seika Pharma within the past three years. Dr. Mimura has received 
grants and/or speaker’s honoraria from Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, Fuji 
Film RI Pharma, Janssen Pharmaceutical, Mochida Pharmaceutical, MSD, Nippon Chemipher, Novartis 
Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Takeda Yakuhin, Tsumura, and Yoshitomi Yakuhin 
within the past three years. Dr. Uchida has received grants from Eisai, Otsuka Pharmaceutical, 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Dainippon-Sumitomo Pharma, Mochida Pharmaceutical, Meiji-Seika Pharmaceutical, and Novartis; 
speaker’s honoraria from Otsuka Pharmaceutical, Eli Lilly, Shionogi, Pfizer, Yoshitomi Yakuhin, 
Dainippon-Sumitomo Pharma, Meiji-Seika Pharma, MSD, and Janssen Pharmaceutical; and advisory panel 
payments from Dainippon-Sumitomo Pharma within the past three years. The other authors have nothing to 
disclose. 
 
 
 
References 
Afridi, M.I., Hina, M., Qureshi, I.S., Hussain, M., 2011. Cognitive disturbance comparison among 
drug-naive depressed cases and healthy controls. J. Coll. Physicians Surg. Pak. 21, 351-355. 
Antikainen, R., Hanninen, T., Honkalampi, K., Hintikka, J., Koivumaa-Honkanen, H., Tanskanen, A., 
Viinamaki, H., 2001. Mood improvement reduces memory complaints in depressed patients. Eur. Arch. 
Psychiatry Clin. Neurosci. 251, 6-11. 
Arts, B., Jabben, N., Krabbendam, L., van Os, J., 2011. A 2-year naturalistic study on cognitive functioning 
in bipolar disorder. Act. Psychiatr. Scand. 123, 190-205. 
Austin, M.P., Mitchell, P., Goodwin, G.M., 2001. Cognitive deficits in depression: possible implications for 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
functional neuropathology. Br. J. Psychiatry. 178, 200-206. 
Baba, K., Baba, H., Noguchi, I., Arai, R., Suzuki, T., Mimura, M., Arai, H., 2010. Executive dysfunction in 
remitted late-life depression: Juntendo University Mood Disorder Projects (JUMP). J. Neuropsychiatry 
Clin. Neurosci. 22, 70-74. 
Bakkour, N., Samp, J., Akhras, K., El Hammi, E., Soussi, I., Zahra, F., Duru, G., Kooli, A., Toumi, M., 2014. 
Systematic review of appropriate cognitive assessment instruments used in clinical trials of 
schizophrenia, major depressive disorder and bipolar disorder. Psychiatry. Res. 216, 291-302. 
Barker, M.J., Greenwood, K.M., Jackson, M., Crowe, S.F., 2004. Cognitive effects of long-term 
benzodiazepine use: a meta-analysis. CNS drugs. 18, 37-48. 
Beevers, C.G., Miller, I.W., 2004. Perfectionism, cognitive bias, and hopelessness as prospective predictors 
of suicidal ideation. Suicide Life Threat. Behav. 34, 126-137. 
Bernstein, I.H., Rush, A.J., Stegman, D., Macleod, L., Witte, B., Trivedi, M.H., 2010. A Comparison of the 
QIDS-C16, QIDS-SR16, and the MADRS in an Adult Outpatient Clinical Sample. CNS Spectr. 15, 
458-468. 
Biringer, E., Mykletun, A., Sundet, K., Kroken, R., Stordal, K.I., Lund, A., 2007. A longitudinal analysis of 
neurocognitive function in unipolar depression. J. Clin. Exp. Neuropsychol. 29, 879-891. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Borkowska, A., Rybakowski, J.K., 2001. Neuropsychological frontal lobe tests indicate that bipolar 
depressed patients are more impaired than unipolar. Bipolar Disord. 3, 88-94. 
Burmester, B., Leathem, J., Merrick, P., 2016. Subjective cognitive complaints and objective cognitive 
function in aging: a systematic review and meta-analysis of recent cross-sectional findings. 
Neuropsychol Rev. 26, 376-393. 
Carter, J.D., Frampton, C.M., Mulder, R.T., Luty, S.E., Joyce, P.R., 2010. The relationship of demographic, 
clinical, cognitive and personality variables to the discrepancy between self and clinician rated 
depression. J. Affect. Disord. 124, 202-206. 
Conradi, H.J., Ormel, J., de Jonge, P., 2011. Presence of individual (residual) symptoms during depressive 
episodes and periods of remission: a 3-year prospective study. Psychol. Med. 41, 1165-1174. 
Crane, M.K., Bogner, H.R., Brown, G.K., Gallo, J.J., 2007. The link between depressive symptoms, 
negative cognitive bias and memory complaints in older adults. Aging Ment. Health. 11, 708-715. 
Evans, V.C., Iverson, G.L., Yatham, L.N., Lam, R.W., 2014. The relationship between neurocognitive and 
psychosocial functioning in major depressive disorder: a systematic review. J. Clin. Psychiatry. 75, 
1359-1370. 
Federico, A., Tamburin, S., Maier, A., Faccini, M., Casari, R., Morbioli, L., Lugoboni, F., 2017. Multifocal 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
cognitive dysfunction in high-dose benzodiazepine users: a cross-sectional study. Neurol. Sci. 38, 
137-142. 
Gorenstein, C., de Carvalho, S.C., Artes, R., Moreno, R.A., Marcourakis, T., 2006. Cognitive performance 
in depressed patients after chronic use of antidepressants. Psychopharmacology (Berl). 185, 84-92. 
Gualtieri, C.T., Morgan, D.W., 2008. The frequency of cognitive impairment in patients with anxiety, 
depression, and bipolar disorder: an unaccounted source of variance in clinical trials. J. Clin. Psychiatry. 
69, 1122-1130. 
Hasselbalch, B.J., Knorr, U., Kessing, L.V., 2011. Cognitive impairment in the remitted state of unipolar 
depressive disorder: a systematic review. J. Affect. Disord. 134, 20-31. 
Inada, T., Inagaki, A., 2015. Psychotropic dose equivalence in Japan. Psychiatry Clin. Neurosci. 69, 
440-447. 
Inagaki, A., Inada, T., 2018. The 27th: Equivalent conversion of novel antidepressants (part 2) Venafaxne. 
Jpn. J. Clin. Psychopharmacol. 21; 547-562 
Lampe, I.K., Sitskoorn, M.M., Heeren, T.J., 2004. Effects of recurrent major depressive disorder on 
behavior and cognitive function in female depressed patients. Psychiatry Res. 125, 73-79. 
Lawrence, C., Roy, A., Harikrishnan, V., Yu, S., Dabbous, O., 2013. Association between severity of 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
depression and self-perceived cognitive difficulties among full-time employees. Prim. Care. 
Companion CNS Disord. 15, PCC. 12m01469. doi: 10.4088/PCC.12m01469. 
McDermott, L.M., Ebmeier, K.P., 2009. A meta-analysis of depression severity and cognitive function. J. 
Affect. Disord. 119, 1-8. 
Montgomery, S.A., Asberg, M., 1979. A new depression scale designed to be sensitive to change. Br. J. 
Psychiatry. 134, 382-389. 
Nagane, A., Baba, H., Nakano, Y., Maeshima, H., Hukatsu, M., Ozawa, K., Suzuki, T., Arai, H., 2014. 
Comparative study of cognitive impairment between medicated and medication-free patients with 
remitted major depression: class-specific influence by tricyclic antidepressants and newer 
antidepressants. Psychiatry Res. 218, 101-105. 
Ozawa, C., Suzuki, T., Mizuno, Y., Tarumi, R., Yoshida, K., Fujii, K., Hirano, J., Tani, H., Rubinstein, E.B., 
Mimura, M., Uchida, H., 2017. Resilience and spirituality in patients with depression and their family 
members: A cross-sectional study. Compr. Psychiatry. 77, 53-59. 
Paelecke-Habermann, Y., Pohl, J., Leplow, B., 2005. Attention and executive functions in remitted major 
depression patients. J. Affect. Disord. 89, 125-135. 
Pomara, N., Lee, S.H., Bruno, D., Silber, T., Greenblatt, D.J., Petkova, E., Sidtis, J.J., 2015. Adverse 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
performance effects of acute lorazepam administration in elderly long-term users: pharmacokinetic and 
clinical predictors. Prog. Neuropsychopharmacol. Biol. Psychiatry. 56, 129-135. 
Potvin, S., Charbonneau, G., Juster, R.P., Purdon, S., Tourjman, S.V., 2016. Self-evaluation and objective 
assessment of cognition in major depression and attention deficit disorder: Implications for clinical 
practice. Compr. Psychiatry 70, 53-64. 
Prado, C.E., Watt, S., Crowe, S.F., 2018. A meta-analysis of the effects of antidepressants on cognitive 
functioning in depressed and non-depressed samples. Neuropsychol. Rev. 28, 32-72. 
Rock, P.L., Roiser, J.P., Riedel, W.J., Blackwell, A.D., 2014. Cognitive impairment in depression: a 
systematic review and meta-analysis. Psychol. Med. 44, 2029-2040. 
Rush, A.J., Carmody, T.J., Ibrahim, H.M., Trivedi, .H., Biggs, M.M., Shores-Wilson, K., Crismon, M.L., 
Toprac, M.G., Kashner, T.M., 2006. Comparison of self-report and clinician ratings on two inventories 
of depressive symptomatology. Psychiatr. Ser. 57, 829-837. 
Rush, A.J., Trivedi, M.H., Ibrahim, H.M., Carmody, T.J., Arnow, B., Klein, D.N., Markowitz, J.C., Ninan, 
P.T., Kornstein, S., Manber, R., Thase, M.E., Kocsis, J.H., Keller, M.B., 2003. The 16-Item Quick 
Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report 
(QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol. Psychiatry. 54, 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
573-583. 
Shilyansky, C., Williams, L.M., Gyurak, A., Harris, A., Usherwood, T., Etkin, A., 2016. Effect of 
antidepressant treatment on cognitive impairments associated with depression: a randomised 
longitudinal study. Lancet Psychiatry. 3, 425-435. 
Soyka, M., 2017. Treatment of Benzodiazepine Dependence. N. Eng. J. Med. 376, 1147-1157. 
Story, T.J., Potter, G.G., Attix, D.K., Welsh-Bohmer, K.A., Steffens, D.C., 2008. Neurocognitive correlates 
of response to treatment in late-life depression. Am. J. Geriatr. Psychiatry 16, 752-759. 
Sullivan, M.J., Edgley, K., Dehoux, E. 1990. A survey of multiple sclerosis, Part 1: perceived cognitive 
problems and compensatory strategy use. Can. J. Rehabil. 4, 99-105. 
Svendsen, A.M., Kessing, L.V., Munkholm, K., Vinberg, M., Miskowiak, K.W., 2012. Is there an 
association between subjective and objective measures of cognitive function in patients with affective 
disorders? Nord. J. Psychiatry. 66, 248-253. 
Tada, M., Uchida, H., Suzuki, T., Abe, T., Pollock, B.G., Mimura, M., 2014. Baseline difference between 
patients' and clinicians' rated illness severity scores and subsequent outcomes in major depressive 
disorder: analysis of the sequenced treatment alternatives to relieve depression data. J. Clin. 
Psychopharmacol. 34, 297-302. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Tourjman, S.V., Juster, R.P., Purdon, S., Stip, E., Kouassi, E., Potvin, S., 2018. The screen for cognitive 
impairment in psychiatry (SCIP) is associated with disease severity and cognitive complaints in major 
depression. Int. J. Psychiatry Clin. Prac. 1-8. 
Trivedi, M.H., 2009. Tools and strategies for ongoing assessment of depression: a measurement-based 
approach to remission. J. Clin. Psychiatry. 70 Suppl 6, 26-31. 
Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., Norquist, G., Howland, 
R.H., Lebowitz, B., McGrath, P.J., Shores-Wilson, K., Biggs, M.M., Balasubramani, G.K., Fava, M., 
2006. Evaluation of outcomes with citalopram for depression using measurement-based care in 
STAR*D: implications for clinical practice. Am. J. Psychiatry. 163, 28-40. 
Uher, R., Farmer, A., Maier, W., Rietschel, M., Hauser, J., Marusic, A., Mors, O., Elkin, A., Williamson, 
R.J., Schmael, C., Henigsberg, N., Perez, J., Mendlewicz, J., Janzing, J.G., Zobel, A., Skibinska, M., 
Kozel, D., Stamp, A.S., Bajs, M., Placentino, A., Barreto, M., McGuffin, P., Aitchison, K.J., 2008. 
Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol. Med. 
38, 289-300. 
Uher, R., Perlis, R.H., Placentino, A., Dernovsek, M.Z., Henigsberg, N., Mors, O., Maier, W., McGuffin, P., 
Farmer, A., 2012. Self-report and clinician-rated measures of depression severity: can one replace the 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
other? Depress. Anxiety. 29, 1043-1049. 
van der Sluiszen, N., Vermeeren, A., Jongen, S., Vinckenbosch, F., Ramaekers, J.G., 2017. Influence of 
Long-Term Benzodiazepine use on Neurocognitive Skills Related to Driving Performance in Patient 
Populations: A Review. Pharmacopsychiatry. 50, 189-196. 
Verdoux, H., Liraud, F., 2000. Neuropsychological function in subjects with psychotic and affective 
disorders. Relationship to diagnostic category and duration of illness. European psychiatry : Eur. 
Psychiatry. 15, 236-243. 
Wagner, A.K., Zhang, F., Soumerai, S.B., Walker, A.M., Gurwitz, J.H., Glynn, R.J., Ross-Degnan, D., 2004. 
Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Arch. Intern. Med. 164, 
1567-1572. 
World Health Organization., 1993. The ICD-10 Classification of Mental and Behavioural Disorders: 
Diagnostic Criteria for Research. (WHO) 
Zimmerman, M., Martinez, J., Attiullah, N., Friedman, M., Toba, C., Boerescu, D.A., 2012. Symptom 
differences between depressed outpatients who are in remission according to the Hamilton Depression 
Rating Scale who do and do not consider themselves to be in remission. J. Affect. Disord. 142, 77-81. 
Zimmerman, M., Posternak, M.A., Chelminski, I., 2004. Defining remission on the Montgomery-Asberg 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
depression rating scale. J. Clin. Psychiatry. 65, 163-168. 
Zlatar, Z.Z., Muniz, M.C., Espinoza, S.G., Gratianne, R., Gollan, T.H., Galasko, D., Salmon, D.P., 2018. 
Subjective cognitive decline, objective cognition, and depression in older Hispanics screened for 
memory impairment. J. Alzheimers. Dis. 63, 949-956. 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Figure legends 
Figure 1. Relationship between MADRS and PDQ total scores (n=102) 
 
Spearman’s correlation analysis found a significant correlation between the MADRS and the J-PDQ total 
scores (r=0.635, p<0.001). 
Abbreviations: J-PDQ, Japanese version of Perceived Deficits Questionnaire; MADRS, 
Montgomery-Asberg Depression Rating Scale 
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Figure 2. Relationship between QIDS and PDQ total scores (n=101) 
 
Spearman’s correlation analysis found a significant correlation between the QIDS and the J-PDQ total 
scores (r=0.789, p<0.001). 
Abbreviations: J-PDQ, Japanese version of Perceived Deficits Questionnaire; QIDS, Quick Inventory of 
Depressive Symptomatology 
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Table 1. Demographic and clinical characteristics of participants (N=102)  
Values are shown as mean±S.D. (range), median (interquartile range), or n (%). 
a.
 The data were available for 101 participants.  
Abbreviations: CPZE, chlorpromazine equivalents; DZPE, diazepam equivalents; IMIE, imipramine 
equivalents; J-PDQ, Japanese version of Perceived Deficits Questionnaire; MADRS, Montgomery-Asberg 
Depression Rating Scale; QIDS, Quick Inventory of Depressive Symptomatology; S.D., standard deviation  
Characteristics  
Age, years 50.5±14.7 (21-90) 
Males 45 (44.1) 
Duration of illness, years 4.0 (2.0-8.3) 
MADRS total score 6.5 (3.0-17.0) 
QIDS total score 9.0 (4.0-14.0)
a
 
J-PDQ total score 23.5 (12.8-36.0) 
Daily doses of antidepressants, IMIE 90.6 (62.5-153.1) 
Daily doses of antipsychotics, CPZE 0.0 (0.0-37.5) 
Daily doses of benzodiazepines, DZPE 5.0 (0.0-10.0) 
Use of any antidepressants 88 (86.3) 
Use of any antipsychotics 34 (33.3) 
Use of any benzodiazepines 74 (72.5) 
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Table 2. Factors associated with subjective cognitive impairment in a multiple linear 
regression analysis, including MADRS total scores for symptom severity (N=102). 
Variables B β 95%CI p-value 
Age, years 
Sex 
-0.099 -0.100 -0.261-0.063 0.226 
 Male Reference    
 Female -0.618 -0.021 -5.269-4.034 0.793 
MADRS total score 1.001 0.621 0.739-1.264 <0.001
*
 
Duration of illness, years -0.197 -0.083 -0.582-0.187 0.310 
Daily doses of 
antidepressants, IMIE 
-0.004 -0.028 -0.028-0.019 0.719 
Daily doses of 
antipsychotics, CPZE -0.003 -0.010 
-0.045-0.040 0.903 
Daily doses of 
benzodiazepines, DZPE 
-0.026 -0.014 -0.335-0.283 0.867 
* 
p-value of <0.05 
Abbreviations: CI, confidence interval; CPZE, chlorpromazine equivalents; DZPE, 
diazepam equivalents; IMIE, imipramine equivalents; MADRS, Montgomery-Asberg 
Depression Rating Scale 
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Table 3. Factors associated with subjective cognitive impairment in a multiple linear 
regression analysis, including QIDS total scores for symptom severity (N=101). 
Variables B β 95%CI p-value 
Age, years 
Sex 
0.005 0.005 -0.123-0.134 0.933 
 Male Reference    
 Female -4.050 -0.138 -7.678- -0.423 0.029
*
 
QIDS total score 2.022 0.838 1.704-2.340 <0.001
*
 
Duration of illness, years -0.023 -0.010 -0.325-0.279 0.878 
Daily doses of 
antidepressants (IMIE) 
-0.016 -0.103 -0.034-0.003 0.097 
Daily doses of 
antipsychotics (CPZE) -0.009 -0.036 
-0.043-0.024 0.569 
Daily doses of 
benzodiazepines (DZPE) 
-0.097 -0.052 -0.336-0.142 0.422 
* 
p-value of <0.05 
Abbreviations: CI, confidence interval; CPZE, chlorpromazine equivalents; DZPE, 
diazepam equivalents; IMIE, imipramine equivalents; QIDS, Quick Inventory of 
Depressive Symptomatology 
Table 4. Comparison of J-PDQ total scores between the QIDS- and MADRS-remitted 
group and the QIDS-non-remitted but MADRS-remitted group 
Variables QIDS- and 
MADRS-remitted 
(n=33) 
QIDS-non-remitted 
but 
MADRS-remitted 
(n=25) 
z-score p-value 
J-PDQ total score 11.0 (5.50-17.50) 25.0 (17.00-31.50) -4.063 <0.001
*
 
MADRS total 
score 
3.00 (0.50-4.50) 3.00 (2.00-4.00) -0.740 0.459 
QIDS total score 3.00 (2.00-4.00) 10.00 (8.00-12.00) -6.504 <0.001
*
 
Values are shown as median (interquartile range). 
Differences were compared by using Mann-Whitney’s U test. 
* 
p-value of <0.05 
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Abbreviations: J-PDQ, Japanese version of Perceived Deficits Questionnaire; MADRS, 
Montgomery-Asberg Depression Rating Scale; QIDS, Quick Inventory of Depressive 
Symptomatology 
 
Table 5. Comparison of J-PDQ total scores between the QIDS- and MADRS-remitted 
group and the QIDS-remitted but MADRS-non-remitted group 
Variables QIDS- and 
MADRS-remitted 
(n=33) 
QIDS-remitted but 
MADRS-non-remitted 
(n=4) 
z-score 
 
p-value 
J-PDQ total 
score 
11.0 (5.50-17.50) 17.00 (13.50-32.50) -1.886 0.058 
MADRS total 
score 
3.00 (0.50-4.50) 15.50 (12.00-18.25) -3.265 <0.001
*
 
QIDS total score 3.00 (2.00-4.00) 5.00 (4.25-5.00) -2.349 0.018 
Values are shown as median (interquartile range). 
Differences were compared by using Mann-Whitney’s U test. 
* 
p-value of <0.05 
Abbreviations: J-PDQ, Japanese version of Perceived Deficits Questionnaire; MADRS, 
Montgomery-Asberg Depression Rating Scale; QIDS, Quick Inventory of Depressive 
Symptomatology 
 
 
